ContraFect Corporation (NASDAQ:CFRX) is scheduled to be announcing its earnings results on Tuesday, November 7th. Analysts expect the company to announce earnings of ($0.11) per share for the quarter.

ContraFect Corporation (NASDAQ:CFRX) last issued its earnings results on Wednesday, August 9th. The biotechnology company reported ($0.07) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.11. On average, analysts expect ContraFect Corporation to post $-0.43 EPS for the current fiscal year and $-0.42 EPS for the next fiscal year.

ContraFect Corporation (CFRX) opened at 1.0858 on Tuesday. The firm’s market capitalization is $79.98 million. ContraFect Corporation has a 12 month low of $0.80 and a 12 month high of $2.70. The stock’s 50 day moving average price is $1.07 and its 200-day moving average price is $1.26.

TRADEMARK VIOLATION NOTICE: This piece of content was originally posted by American Banking News and is the sole property of of American Banking News. If you are viewing this piece of content on another domain, it was stolen and reposted in violation of U.S. & international copyright & trademark laws. The correct version of this piece of content can be accessed at

About ContraFect Corporation

ContraFect Corporation, a clinical-stage biotechnology company, focuses on discovering and developing therapeutic protein and antibody products for the treatment of life-threatening infectious diseases in the United States. Its lead product candidates consist of CF-301, a lysin that completed Phase 1 human clinical trials for the treatment of Staph aureus bacteremia, including endocarditis caused by methicillin-resistant or methicillin-susceptible Staph aureus; and CF-404, a combination of human monoclonal antibodies (mAbs) for the treatment of life-threatening seasonal and pandemic varieties of human influenza.

Earnings History for ContraFect Corporation (NASDAQ:CFRX)

Receive News & Ratings for ContraFect Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ContraFect Corporation and related companies with's FREE daily email newsletter.